Tested a targeted drug plus fewer cancers treatments for children
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial studies whether a targeted medicine that blocks MEK can work better than chemotherapy for certain slow-growing brain tumors in children. You may qualify if your tumor has specific genetic features and has not already been treated with non-surgery therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age is at least 1 month and at most 25 years
- Your tumor type matches a specific low-grade brain tumor (grade 1 glioma or related types) confirmed by expert review
- Your tumor must have no BRAF change at the specific V600 point, and must have 7q34 duplication or a KIAA1549-BRAF fusion
- Your tumor should not have certain gene changes (like midline H3 mutations or IDH1 mutations), and should not be a DIPG or SEGA
- You must be able to do study procedures and have good blood, liver, kidney, and heart function
- You can’t be pregnant or breastfeeding, and there are strict birth-control rules during and after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (dabrafenib and trametinib) and immunotherapy (nivolumab) for children and young adults with certain BRAF gene changes in their glioma. It aims to see if this drug combination can shrink tumors or stop them from growing.
This trial tests two targeted drugs (dabrafenib and trametinib) for children and young adults with a specific type of low-grade brain tumor that has a BRAF V600 mutation. The drugs work by blocking signals that help the tumor grow.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This trial tests a combination of two drugs (mirdametinib and vinblastine) for children and young adults with a type of slow-growing brain tumor called low-grade glioma that has certain genetic changes. It may be an option for people who have not received any previous treatment for their tumor.
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
Hear when a new Pleomorphic Xanthoastrocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.